{
    "nctId": "NCT05465031",
    "briefTitle": "Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)",
    "officialTitle": "Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents, Sacubitril/Valsartan, Angiotensin II Type 1 Receptor Blockers, Angiotensin Receptor Antagonists, Molecular Mechanisms of Pharmacological Action, Heart Failure, Cardiac Toxicity, Cancer, Therapy-Related, Cancer Therapy-Related Cardiac Dysfunction, Cardiotoxicity",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 600,
    "primaryOutcomeMeasure": "Decrease in left ventricular ejection fraction \u2265 5%",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent\n* Female gender, aged 18 years and over\n* Patients with histologically confirmed breast cancer and complete assessment of tumor phenotype (ER, PR, HER2, Ki67)\n* Ability to take oral medication and willingness to adhere to the planned regimen\n* Tumor grade IA-IIIC or oligometastatic grade IV\n* Radical treatment plan including surgery\n* Plan of use of systemic treatment (preoperative, postoperative or combined) with anthracyclines and/or anti-HER2 drugs\n* ECOG 0-2 general status\n* LVEF \u2265 50% as assessed by echocardiography\n* Sinus rhythm\n\nExclusion Criteria:\n\n* Prior anthracycline-based chemotherapy and/or left-sided radiotherapy (prior to diagnosis of the cancer being the present cause of therapy)\n* Clinically relevant HF (NYHA II-IV)\n* MI within the last \\< 3 months\n* Symptomatic hypotension or SBP \\< 90 mmHg\n* Significant valvular disease, symptomatic coronary artery disease (CCS\\>2), significant AV block, symptomatic sinus node dysfunction\n* Expected survival \\<12 months\n* GFR\\<30 ml/min/1.73 m2 (screening visit)\n* K+\\>5.5mmol/L (screening visit)\n* Contraindications to ACE-I/ARB or LCZ696 if not listed among criteria\n* Active untreated liver disease\n* Pregnancy\n* Contraindications to cardiac MRI, including allergy to gadolinium-containing contrast agent or presence of implanted materials or devices prohibited for MRI\n* Conditions/circumstances that may lead to non-compliance with medical staff recommendations (e.g. active drug/alcohol dependence, poorly controlled mental illness)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}